An interventional study of Group Session and Coaching Call in Cancer Survivorship and Sexual Function Disturbances, sponsored by Dana-Farber Cancer Institute. Active, not recruiting at 1 site in United States. Open to female participants aged 19 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-02-24.
Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Sexual Dysfunctions, Psychological with a site in United States — 3 open to participants now, 6 under way, none of them phase 3. Sexual Dysfunctions, Psychological · United States.
Among the 62 studies in Sexual Dysfunctions, Psychological with a site in United States, this one is the 36th largest by enrollment of the 59 interventional ones that give a count, is one of 2 that started in 2025, is one of 14 with no phase, and was the 61st registered.
138 studies on the registry are indexed under Sexual Dysfunctions, Psychological; 10 are open to participants now.
Browse Sexual Dysfunctions, Psychological studies →3 of the 62 studies in Sexual Dysfunctions, Psychological with a site in United States are open now. Recruiting first, the newest first:
Urological Research Network, LLC · Sites in United States
Ages 50–80 · Men only · Healthy volunteers
University of Illinois at Chicago · Sites in United States
Ages 18+ · Women only
San Diego Sexual Medicine · Sites in United States
Ages 21–75 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Sexual Dysfunctions, Psychological studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 19 Years to 49 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 16 · Phase 3 27 · Phase 4 2
First in 2002; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is below the median of 100 across 114 interventional studies indexed under Sexual Dysfunctions, Psychological.
Median enrollment 196 across the 59 interventional studies, 18 across the 1 observational. Of the 53 that completed or were terminated, 20 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 62 have an industry lead sponsor. The 10 most frequent:
Dana-Farber Cancer Institute is the lead sponsor of 836 studies on the registry; 121 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 78 (68%) have results posted.
Dana-Farber Cancer Institute has 2 studies filed under Sexual Dysfunctions, Psychological — fewer than ten, so there is no comparison to draw.
2 of the studies in Sexual Dysfunctions, Psychological with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05777031University of MiamiSafety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease | 2027-01-15 |
| NCT06458049Dana-Farber Cancer InstituteSexual Health and Rehabilitation Online (SHAREonline) | 2027-05-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 62 studies in Sexual Dysfunctions, Psychological with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
SHAREonline is a study for young female cancer survivors that are experiencing changes in sexual health and function.
The purpose of this research is to compare two brief interventions delivered by videoconference to learn if they help women effectively manage these changes and restore sexual health and functioning.
The purpose of this research is to compare two brief interventions delivered by videoconference to learn if they help women effectively manage these changes and restore sexual health and functioning.
Participants in this study would first complete health questionnaires and then be randomized to take part in one of two types of education sessions delivered by an instructor over videoconference: 1) Group education session or 2) Individual self-management session.
About 56 women will receive the group education session and about 28 will receive the individual self-management session.
It is expected that about 84 women will take part in this study.
Exclusion Criteria
Participants will receive: * One online group session structured around three 60-minute modules and creation of a personal action plan * Single Coaching phone call at one month * Questionnaires to complete at baseline, 2 and 4 Months
Behavioral: Group Session · Behavioral: Coaching Call
Brief individualized session with online and written materials and guidance. All Participants will complete study questionnaires at baseline, 2 months and 4 months post intervention
Behavioral: Educational Materials
On-line educational session-3 modules-1 hour each for a total of 3 hours
Single Coaching phone call at one month
Individual videoconference session in which participants will receive a pdf of the American Cancer Society booklet, 'Sex and the Adult Female with Cancer
Change in Sexual Function
The Female Sexual Function Index (FSFI Full Scale Score), is 19-item instrument which measures sexual function, including desire, orgasm, pain and satisfaction.
Time frame: Baseline to 2 months
Change in Emotional Distress
BSI-18 (Brief Symptom Inventory) The BSI-18 is a well-validated screening measure of psychological distress with subscales measuring anxiety, depression and somatization that is frequently used with oncology populations.
Time frame: Baseline to 2 month
Change in Sexual Function
The Female Sexual Function Index (FSFI Full Scale Score), is 19-item instrument which measures sexual function, including desire, orgasm, pain and satisfaction.
Time frame: Baseline to 4 months
Change in Emotional Distress
BSI-18 (Brief Symptom Inventory) The BSI-18 is a well-validated screening measure of psychological distress with subscales measuring anxiety, depression and somatization that is frequently used with oncology populations.
Time frame: Baseline to 4 months
Enrollment Rate
Measured through study accrual with a benchmark of enrollment greater than or equal to 40% of eligible candidates
Time frame: Baseline to 1 month
Intervention Acceptability Rate
Intervention Satisfaction Questionnaire will be assessed using a benchmark mean score of 4
Time frame: Up to 1 month-post intervention
Study Engagement Rate
Measured through study engagement with a benchmark of study engagement greater than or equal to 70% of eligible candidates
Time frame: Baseline to 1 month
Intervention Completion Rate
Measured through intervention completion with a benchmark of intervention completion greater than or equal to 60% of eligible candidates
Time frame: Baseline to 4 months
Distress about Sexual Function
Sexual Distress Scale-short form (SDS-SF) is a 5-item measure which assesses distress about sexual function.
Time frame: Baseline to 2 months
Distress about Sexual Function
Sexual Distress Scale-short form (SDS-SF) is a 5-item measure which assesses distress about sexual function.
Time frame: Baseline to 4 months
Sexual Function, Satisfaction and Sexual Inactivity
PROMIS Sexual Function and Satisfaction (PROMIS SexFS) is a short screening
Time frame: Baseline to 2 months
Sexual Self-efficacy
Sexual Self-Efficacy Scale is a 5-item scale developed to measure perceived sexual self-efficacy to address sexual health after cancer.
Time frame: Baseline to 2 months
Sexual Self-efficacy
Sexual Self-Efficacy Scale is a 5-item scale developed to measure perceived sexual self-efficacy to address sexual health after cancer.
Time frame: Baseline to 4 months
Coaching Satisfaction Summary
Brief participant questionnaire to provide feedback about coaching session.
Time frame: Up to 1 month post-coaching session
Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data can be shared no earlier than 1 year following the date of publication
Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for May 2027, 27 months after the start.
Of 30 non-industry interventional studies with no phase under Sexual Dysfunctions, Psychological, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 24. This study's planned 27 months is above that.
Counting every sponsor, half of 30 studies reached it within 21 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sexual Dysfunctions, Psychological →
Dana-Farber Cancer Institute →